tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Nuvilex Inc.'

FDA Grants Orphan Drug Designation to Nuvilex, Inc. for Pancreatic Cancer Treatment

SILVER SPRING, Md., Dec. 22, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex’s pancreatic cancer treatment combines Nuvilex’s patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box(R), with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are ...

Read More →
0

Stock Market Media Issues Nuvilex, Inc. Road to Phase III Clinical Trials Report

Stock Market Media Issues Nuvilex, Inc. Road to Phase III Clinical Trials Report

Stock Market Media Group, a research and content development investor relations firm, issued its Third Quarter Update and the first installment of its Nuvilex, Inc. (OTCQB: NVLX): Road to Phase III Clinical Trials Report today.  

After reviewing a number of recent events at the company including, an acquisition of exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment, and the return of 100 million shares to the company’s treasury, we have released our latest update and report on ...

Read More →
0

Nuvilex, Inc. Moves Closer to Head to Head with Eli Lilly in Phase III Clinical Trials

Nuvilex, Inc. Moves Closer to Head to Head with Eli Lilly in Phase III Clinical Trials

Written by ι Stock Market Media Group Staff — July 25, 2013

Nuvilex, Inc. (OTCQB: NVLX) is currently preparing the way to challenge Eli Lilly’s (NYSE: LLY) blockbuster cancer drug, Gemzar, and doing so with the knowledge that in two independent mid-phase clinical trials, the company’s treatment involving its proprietary living cell encapsulation technology has outperformed the pharmaceutical giant.  Nuvilex has produced better results when compared to historical data for Gemzar, and now the company is ready to use real time, head to ...

Read More →
0

Nuvilex, Inc. Acquisition Could Be Steal of the Century and Worth Billions

Nuvilex, Inc. Acquisition Could Be Steal of the Century and Worth Billions

Written by ι Stock Market Media Group Staff — July 18, 2013

In a recently announced acquisition deal, Nuvilex, Inc. (OTCQB: NVLX), pulled off what can only be described as the steal of the century.  The company was able to secure a deal that allowed it to “cherry-pick” the exact piece of the pie Nuvilex wanted from another company.  And, what was the exact piece of the pie Nuvilex wanted – Bio Blue Bird AG (BBB) and more importantly, its worldwide licenses ...

Read More →
0

Nuvilex, Inc. Will Enter Phase III Trials with Advantages Using Cell Encapsulation

Nuvilex, Inc. Will Enter Phase III Trials with Advantages Using Cell Encapsulation

Written by ι Stock Market Media Staff — July 9, 2013

When Nuvilex, Inc. (OTCQB: NVLX) enters its pivotal Phase III clinical trial using its cell encapsulation technology combined with the anti-cancer drug ifosfamide for the treatment of late stage, inoperable pancreatic cancer, the company will do so with a number of distinct advantages.  The encapsulated cells capable of converting ifosfamide into its “cancer-killing” form could very well prove to be the “magic bullet” that catapults Nuvilex’s treatment to the standard therapy ...

Read More →
0

Nuvilex, Inc. a Biotech Developing Treatments for Healthcare’s Hard Targets

Nuvilex, Inc. a Biotech Developing Treatments for Healthcare’s Hard Targets

Written by ι Stock Market Media Group Staff — June 26, 2013

Nuvilex, Inc. (OTCQB: NVLX) executives aren’t daunted by the statistics.  As a matter of fact, they’re aware the research they do is directed towards attacking what the company’s Chief Operations Officer, Dr. Gerald Crabtree, calls two of cancer’s “hard targets.”  “Pancreatic cancer and brain cancers represent two such targets.  Pancreatic cancer because it doesn’t present overt symptoms until the cancer is at an advanced stage; therefore, it is more difficult to ...

Read More →
0
Page 1 of 4 1234
ContactUs.com